What's in Vanderbilt-Ingram Cancer Center's pipeline?

Vanderbilt-Ingram Cancer Center has 11 drugs in our index: 3 marketed, 0 filed, 3 in Phase 3, 2 in Phase 2, 2 in Phase 1.

Which companies overlap with Vanderbilt-Ingram Cancer Center's portfolio?

Top competitors by shared drug class: AmMax Bio, Inc., Aronora, Inc., Assistance Publique - Hôpitaux de Paris, Astellas Pharma Europe B.V., Astellas Pharma Global Development, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/vanderbilt-ingram-cancer-center.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Vanderbilt-Ingram Cancer Center — Portfolio Competitive Intelligence Brief

Vanderbilt-Ingram Cancer Center pipeline: 3 marketed, 0 filed, 3 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 3 Phase 3 2 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Bisphosphonates	Bisphosphonates	marketed			Other
Copper Cu 64 Dotatate	Copper Cu 64 Dotatate	marketed	Radiopharmaceutical; somatostatin receptor agonist imaging agent	Somatostatin receptor 2 (SSTR2)	Oncology
Cetuximab (EGFR inhibitor)	Cetuximab (EGFR inhibitor)	marketed	EGFR inhibitor (monoclonal antibody)	EGFR (Epidermal Growth Factor Receptor)	Oncology
TGR-1202	TGR-1202	phase 3	PI3K delta inhibitor	PI3K delta	Oncology
Magic Mouthwash	Magic Mouthwash	phase 3	Topical oral rinse combination therapy		Oncology
cyclosporine ophthalmic emulsion	cyclosporine ophthalmic emulsion	phase 3	immunosuppressant	calcineurin	Ophthalmology

Therapeutic area mix

Oncology · 4
Other · 3
Ophthalmology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AmMax Bio, Inc. · 1 shared drug class
Aronora, Inc. · 1 shared drug class
Assistance Publique - Hôpitaux de Paris · 1 shared drug class
Astellas Pharma Europe B.V. · 1 shared drug class
Astellas Pharma Global Development, Inc. · 1 shared drug class
Astellas Pharma Inc · 1 shared drug class
AstraZeneca · 1 shared drug class
Addpharma Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Vanderbilt-Ingram Cancer Center:

Cite this brief

Drug Landscape (2026). Vanderbilt-Ingram Cancer Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/vanderbilt-ingram-cancer-center. Accessed 2026-05-16.